Drug Profile
Research programme: retinal degeneration therapeutics - Lineage Cell Therapeutics/University of Pittsburgh Medical Center
Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator University of Pittsburgh Medical Center
- Developer Lineage Cell Therapeutics
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intraocular, Implant)
- 03 Sep 2019 Preclinical trials in Retinal disorders in USA (unspecified route) before September 2019
- 03 Sep 2019 Pharmacodynamics data from a preclinical trial in Retinal disorders released by Lineage Cell Therapeutics